<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2754704d-6f02-40fd-a403-6463162f5777"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">Amphetamine Sulfate Tablets, USP CII </content>
   </title>
   <effectiveTime value="20250501"/>
   <setId root="53d40847-e0d3-48ec-81a7-ec5478553565"/>
   <versionNumber value="17"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals NY LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals of New York, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1563" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1564" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1563" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1564" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1563" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1564" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1563" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69238-1564" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f19fab65-02e1-41a4-87f1-bf86813ff595"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69238-1563" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Amphetamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69238-1563-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180928"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211139" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180928"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69238-1564" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Amphetamine Sulfate</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Amphetamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69238-1564-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180928"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211139" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180928"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="blue" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="4" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_58eab01c-8cb9-42f4-b474-22f12b925e76">
               <id root="d69a1670-9e1f-4bbb-9194-3f79df88f59b"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: ABUSE, MISUSE, AND ADDICTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amphetamine sulfate tablets have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including amphetamine sulfate, can result in overdose and death (see <linkHtml href="#www.splportal.comLINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">OVERDOSAGE</linkHtml>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Before prescribing amphetamine sulfate tablets, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout amphetamine sulfate tablets treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction (see <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml> and <linkHtml href="#www.splportal.comLINK_9d3ffb31-5d81-4f04-aeba-cb0d00fc6125">DRUG ABUSE AND DEPENDENCE</linkHtml>).</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_92d7a166-a8db-44eb-a714-413b76c9c514">
               <id root="a40f86fa-7c85-426a-a98d-4465f7ff6e01"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Amphetamine sulfate, USP is a sympathomimetic amino of the amphetamine group. It is a white powder. It has a slightly bitter taste. Its solutions are acid to litmus, having a pH of 5 to 8. It is freely soluble in water, slightly soluble in alcohol and practically insoluble in ether. </paragraph>
                  <paragraph>Each tablet, for oral administration contains 5 mg or 10 mg of amphetamine sulfate, USP. Each tablet also contains the following inactive ingredients:  colloidal silicon dioxide, crospovidone, microcrystalline cellulose, stearic acid, and talc. The 10 mg tablet also contains FD&amp;C Blue #1 aluminum lake.</paragraph>
                  <paragraph> Structural Formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amphetamine-sulfate-tablets-usp-cii-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8601e4ea-2ea2-4294-b024-e27df4c3dbcf">
               <id root="e5ecaec8-aee4-4c81-9c91-46ca405e7248"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures, and weak bronchodilator, and respiratory stimulant action.</paragraph>
                  <paragraph>Amphetamine, as the racemic form, differs from dextroamphetamine in a number of ways. The l-isomer is more potent than the d-isomer in cardiovascular activity, but much less potent in causing CNS excitatory effects. The racemic mixture also is less effective as an appetite suppressant when compared to dextroamphetamine. There is neither specific evidence which clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how those effects relate to the condition of the central nervous system. </paragraph>
                  <paragraph>Drugs in this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects, may be involved, for example. Adult obese subjects instructed in dietary management and treated with "anorectic" drugs lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials. </paragraph>
                  <paragraph>The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The origins of the increased weight loss due to the various possible drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and nondrug factors on weight loss. </paragraph>
                  <paragraph>The natural history of obesity is measured in years, whereas the studies cited are restricted to few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1024c95e-ba37-4a0a-a428-9322ac1bc69a">
               <id root="fecae2e2-1b80-44c7-9792-5466ea3089fd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Amphetamine sulfate tablets, USP 5 mg and 10 mg are indicated for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">1. Narcolepsy</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2. Attention Deficit Disorder with Hyperactivity</content> as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.</paragraph>
                  <paragraph>
                     <content styleCode="bold">3. Exogenous Obesity</content> as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_8601e4ea-2ea2-4294-b024-e27df4c3dbcf">CLINICAL PHARMACOLOGY</linkHtml>
                     </content>) should be weighed against possible risks inherent in use of the drug, such as those described below.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_03a54ae7-107e-496e-b82e-9b32df138749">
               <id root="3064e722-d234-4f31-85e1-58c8e6b6c554"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered" styleCode="Disk">
                     <item>Known hypersensitivity to amphetamine products.</item>
                     <item>During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) (see <content styleCode="bold">
                           <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                        </content>).</item>
                  </list>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">
               <id root="96e3fcb9-6d04-4569-9aea-db368c15ea5d"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Amphetamine sulfate tablets have a high potential for abuse and misuse. The use of amphetamine sulfate tablets exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Amphetamine sulfate can be diverted for non-medical use into illicit channels or</paragraph>
                  <paragraph>distribution (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_9d3ffb31-5d81-4f04-aeba-cb0d00fc6125">DRUG ABUSE AND DEPENDENCE</linkHtml>
                     </content>). Misuse and abuse of CNS stimulants, including amphetamine sulfate tablets, can result in overdose and death (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">OVERDOSAGE</linkHtml>
                     </content>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                  <paragraph>Before prescribing amphetamine sulfate tablets, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give amphetamine sulfate tablets to anyone else. Throughout amphetamine sulfate tablets treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended ADHD dosages.</paragraph>
                  <paragraph>Avoid amphetamine sulfate tablets use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Increased Blood Pressure and Heart Rate</content>
                  </paragraph>
                  <paragraph>CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Psychiatric Adverse Reactions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="underline">Exacerbation Pre-Existing Psychosis</content>
                     </content>
                  </paragraph>
                  <paragraph>CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="underline">Induction of a Manic Episode in Patients with Bipolar Disorder</content>
                     </content>
                  </paragraph>
                  <paragraph>CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating amphetamine sulfate tablets, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="underline">New Psychotic or Manic Symptoms</content>
                     </content>
                  </paragraph>
                  <paragraph>CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic episodes occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing amphetamine sulfate tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Long-Term Suppression of Growth in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth (weight and height) in amphetamine sulfate tablets-treated pediatric patients treated with CNS stimulants.</paragraph>
                  <paragraph>Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_d88f3cba-ae70-484f-9601-5f9595bf2c8e">PRECAUTIONS, PEDIATRIC USE</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Seizures</content>
                  </paragraph>
                  <paragraph>There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Peripheral Vasculopathy, including Raynaud's phenomenon</content>
                  </paragraph>
                  <paragraph>Stimulants, including amphetamine sulfate, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulants.</paragraph>
                  <paragraph>Careful observation for digital changes is necessary during amphetamine sulfate tablets treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_9ad33611-5fb5-407b-9039-5f868c3d2ab2">DRUG INTERACTIONS</linkHtml>
                     </content>). The co-administration with cytochrome P450 CYP2D6 inhibitors may also increase the risk with increased exposure to amphetamine sulfate tablets. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_9ad33611-5fb5-407b-9039-5f868c3d2ab2">DRUG INTERACTIONS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</paragraph>
                  <paragraph>Concomitant use of amphetamine sulfate with MAOI drugs is contraindicated (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_03a54ae7-107e-496e-b82e-9b32df138749">CONTRAINDICATIONS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Discontinue treatment with amphetamine sulfate and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of amphetamine sulfate with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate amphetamine sulfate with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                  </paragraph>
                  <paragraph>CNS stimulants, including amphetamine sulfate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Assess the family history and clinically evaluate patients for tics or Tourette’s syndrome before initiating amphetamine sulfate tablets. Regularly monitor patients for the emergence or worsening of tic or Tourette’s syndrome with amphetamine sulfate tablets, and discontinue.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4ea26a5c-19b6-4b9d-8e9e-7eff1274fa61">
               <id root="ecaf9c42-3cc5-400a-a1b8-f5ab9eddb35d"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250501"/>
               <component>
                  <section ID="LINK_0d937cf0-d092-4ede-96e6-4e4f4b7c441c">
                     <id root="0a559803-e12f-41a2-bced-9dabd33ddfa6"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_194ab61f-09f5-4465-a85a-ba9ec6c68f7b">
                     <id root="e73967a3-06ee-46fb-912f-97fc01898d44"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                           </content>
                        </paragraph>
                        <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of amphetamine sulfate tablets, which can lead to overdose and death, and proper disposal of any unused drug (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>, <linkHtml href="#www.splportal.comLINK_9d3ffb31-5d81-4f04-aeba-cb0d00fc6125">DRUG ABUSE AND DEPENDENCE</linkHtml>, </content>and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">OVERDOSAGE</linkHtml>
                           </content>). Advise patients to store amphetamine sulfate tablets in a safe place, preferably locked, and instruct patients to not give amphetamine sulfate tablets to anyone else.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with amphetamine sulfate tablets use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Increased Blood Pressure and Heart Rate</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise patients that amphetamine sulfate tablets can elevate blood pressure and heart rate (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Psychiatric Adverse Reactions</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise patients that amphetamine sulfate tablets, at recommended doses, can cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Long-Term Suppression of Growth in Pediatric Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise patients that amphetamine sulfate tablets, may cause slowing of growth including weight loss (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Instruct patients beginning treatment with amphetamine sulfate about the risk of peripheral vasculopathy, including Raynaud's Phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</item>
                           <item> Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</item>
                           <item> <content styleCode="bold">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking amphetamine sulfate.</content>
                           </item>
                           <item>
                              <content styleCode="bold"> </content>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Serotonin Syndrome</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Caution </content>patients about the risk of serotonin syndrome with concomitant use of amphetamine sulfate tablets and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid <content styleCode="italics">(</content>see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_03a54ae7-107e-496e-b82e-9b32df138749">CONTRAINDICATIONS</linkHtml>, <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                              <content styleCode="italics">, </content>
                           </content>and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_9ad33611-5fb5-407b-9039-5f868c3d2ab2">DRUG INTERACTIONS</linkHtml>
                           </content>). Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise patients that motor and verbal tics and worsening of Tourette’s syndrome may occur during treatment with amphetamine sulfate tablets. Instruct the patients to notify their healthcare provider of emergence or worsening of tics or Tourette’s syndrome occurs (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicle; the patient should therefore be cautioned accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9ad33611-5fb5-407b-9039-5f868c3d2ab2">
                     <id root="835de69e-92e4-416b-a9da-7b3e282ada28"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>MAO inhibitors- MAOI antidepressants, as well as a metabolic of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.</paragraph>
                        <paragraph>Serotonergic Drugs- The concomitant use of amphetamine sulfate tablets and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during amphetamine sulfate tablets initiation or dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the concomitant serotonergic drug(s) (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_4ea26a5c-19b6-4b9d-8e9e-7eff1274fa61">PRECAUTIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>CYP2D6 Inhibitors- The concomitant use of amphetamine sulfate tablets and CYP2D6 inhibitors may increase the exposure of amphetamine sulfate tablets compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during amphetamine sulfate tablets initiation and after a dosage increase. If serotonin syndrome occurs, discontinue amphetamine sulfate tablets and the CYP2D6 inhibitor (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                           </content>, <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">OVERDOSAGE</linkHtml>
                           </content>). Examples of CYP2D6 inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Acidifying agents</content> - Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adrenergic blockers</content> - Adrenergic blockers are inhibited by amphetamines.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Alkalinizing agents</content> - Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the action of amphetamines.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antidepressants tricyclic</content> - Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antihistamines</content> - Amphetamines may counteract the sedative effect of antihistamines.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antihypertensives</content> - Amphetamines may antagonize the hypotensive effects of antihypertensives.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chlorpromazine</content> - Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamine, and can be used to treat amphetamine poisoning.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Ethosuximide</content> - Amphetamines may delay intestinal absorption of ethosuximide.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Haloperidol</content> - Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Lithium carbonate</content> - The antiobesity and stimulatory effects of amphetamines may be inhibited by lithium carbonate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Meperidine</content> - Amphetamines potentiate the analgesic effect of meperidine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Methenamine therapy</content> - Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Norepinephrine</content> - Amphetamines enhance the adrenergic effect of norepinephrine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Phenobarbital</content> - Amphetamines may delay intestinal absorption of phenobarbital. Co-administration of phenobarbital may produce a synergistic anticonvulsant action.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Phenytoin</content> - Amphetamines may delay intestinal absorption of phenytoin; co- administration of phenytoin may produce a synergistic anticonvulsant action.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Propoxyphene</content> - In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Veratrum alkaloids</content> - Amphetamines inhibit the hypotensive effect of veratrum alkaloids.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b5b6cbf4-3639-4653-87ff-97bf639521ce">
                     <id root="baf67214-ee3b-4d82-baaf-b66e158d3d6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Drug/Laboratory Test interactions</title>
                     <text>
                        <paragraph>Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fb04f1c1-4ae3-43ec-946d-2f3683aa9318">
                     <id root="d0b5e9be-52ee-4ae3-bcdd-79a6703ebc63"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis/Mutagenesis</title>
                     <text>
                        <paragraph>Mutagenicity studies and long term studies in animals to determine the carcinogenic potential of amphetamine sulfate have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1b33803c-5c6a-4e19-b747-1dfa9c1d2058">
                     <id root="a51ca00a-2c11-472c-ac60-878139fd1ff6"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Teratogenic Effects</content>
                        </paragraph>
                        <paragraph>Dextroamphetamine sulfate has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. There are no adequate and well-controlled studies in pregnant women. Amphetamine sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Nonteratogenic Effects</content>
                        </paragraph>
                        <paragraph>Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude. </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_55fc3e15-8c86-4dd9-bfa9-66309957d525">
                     <id root="1932996e-4bce-41c8-b071-748528a0c834"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d88f3cba-ae70-484f-9601-5f9595bf2c8e">
                     <id root="415363d4-abb7-4cbf-a1ad-c267abd4b6e9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Long-term effects of amphetamines in children have not been well established.</paragraph>
                        <paragraph>Amphetamines are not recommended for use as anorectic agents in children under 12 years of age, or in children under 3 years of age with Attention Deficit Disorder with Hyperactivity described under <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_1024c95e-ba37-4a0a-a428-9322ac1bc69a">INDICATIONS AND USAGE</linkHtml>
                           </content>.</paragraph>
                        <paragraph>Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.</paragraph>
                        <paragraph>Data is inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore growth should be monitored during treatment. Drug Treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the child. The decision to prescribe amphetamines should depend on the physician's assessment of the chronicity and severity of the child's symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.</paragraph>
                        <paragraph>When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9ca949a0-5646-4d44-a93d-2e2a4b8f7f0c">
               <id root="22616af5-5c47-4fe2-a827-e229016df567"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular</content>
                  </paragraph>
                  <paragraph>Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Central Nervous System</content>
                  </paragraph>
                  <paragraph>Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and verbal tics and Tourette's syndrome.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal</content>
                  </paragraph>
                  <paragraph>Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects when amphetamines are used for other than the anorectic effect.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Allergic</content>
                  </paragraph>
                  <paragraph>Urticaria</paragraph>
                  <paragraph>
                     <content styleCode="bold">Endocrine</content>
                  </paragraph>
                  <paragraph>Impotence, changes in libido, and frequent or prolonged erections. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Musculoskeletal</content>
                  </paragraph>
                  <paragraph>Rhabdomyolysis</paragraph>
                  <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1‑800-FDA-1088 or <content styleCode="italics">
                        <content styleCode="underline">www.fda.gov/medwatch</content>
                     </content>.</content>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9d3ffb31-5d81-4f04-aeba-cb0d00fc6125">
               <id root="43ec98cf-7547-4996-86d9-3b00e50bf04a"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Controlled Substance</content>
                  </paragraph>
                  <paragraph>Amphetamine sulfate tablets contain amphetamine, a Schedule II controlled substance.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Abuse</content>
                  </paragraph>
                  <paragraph>Amphetamine sulfate tablets have a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                     </content>). Amphetamine sulfate tablets can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                  <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                  <paragraph>Misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including amphetamine sulfate, can result in overdose and death (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">OVERDOSAGE</linkHtml>
                     </content>), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dependence</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Physical Dependence</content>
                  </paragraph>
                  <paragraph>Amphetamine sulfate tablets may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                  <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including amphetamine sulfate tablets include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Tolerance</content>
                  </paragraph>
                  <paragraph>Amphetamine sulfate tablets may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2900ee21-2bf0-4c94-bb28-b016337dd67c">
               <id root="db0e0989-886a-466c-b5e3-bdc0fc158cfd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose</content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                     <item> CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                     <item> Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management</content>
                  </paragraph>
                  <paragraph>Consider the possibility of multiple drug ingestion. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_a8f5e226-19d2-44af-8055-cf52848353a0">
               <id root="61c8b8fd-4494-4dcd-8a91-778b2d91c292"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Regardless of indication, amphetamine should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of resulting insomnia. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Narcolepsy</content>
                  </paragraph>
                  <paragraph>Usual dose is 5 to 60 milligrams per day in divided doses depending on the individual patient response. </paragraph>
                  <paragraph>Narcolepsy seldom occurs in children under 12 years of age; however, when it does, amphetamine sulfate tablets, USP may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia) dosage should be reduced. Give the first dose on awakening; additional doses (5 or 10 mg) at intervals of 4 to 6 hours. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Attention Deficit Disorder with Hyperactivity</content>
                  </paragraph>
                  <paragraph>Not recommended for children under 3 years of age. </paragraph>
                  <paragraph>
                     <content styleCode="underline">In children from 3 to 5 years of age,</content> start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained. </paragraph>
                  <paragraph>
                     <content styleCode="underline">In children 6 years of age or older,</content> start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 milligrams per day. </paragraph>
                  <paragraph>With tablets give first dose on awakening; additional doses (1 to 2) at intervals of 4 to 6 hours. </paragraph>
                  <paragraph>Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</paragraph>
                  <paragraph>Prior to treating patients with amphetamine sulfate tablets, assess:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) (see <content styleCode="bold">
                           <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                        </content>).</item>
                     <item> the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome (see <content styleCode="bold">
                           <linkHtml href="#www.splportal.comLINK_2ca356bc-f723-4904-83d2-1d4178ea8a75">WARNINGS</linkHtml>
                        </content>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Exogenous Obesity</content>
                  </paragraph>
                  <paragraph>Usual dosage is up to 30 mg daily, taken in divided doses of 5 mg to 10 mg, 30 to 60 minutes before meals. Not recommended for this use in children under 12 years of age.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_094fa980-cb70-47d9-a0bd-b568e383faa1">
               <id root="f534d79f-1c98-4718-a061-1a6c6c5a8e38"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Amphetamine Sulfate Tablets USP,<content styleCode="bold"> 5 mg</content> are supplied as white, round biconvex tablets, plain on one side, and ‘5’ with score on the other side.</paragraph>
                  <paragraph>They are available as follows:</paragraph>
                  <paragraph>Bottles of 100:                        NDC 69238-1563-1</paragraph>
                  <paragraph>Amphetamine Sulfate Tablets USP,<content styleCode="bold"> 10 mg </content>are supplied as blue, round biconvex tablets, plain on one side, and ‘10’ with double scores on the other side.</paragraph>
                  <paragraph>They are available as follows:</paragraph>
                  <paragraph>Bottles of 100:                        NDC 69238-1564-1</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a well-closed container, as defined in the USP.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals of New York, LLC<br/>
                     </content>Brookhaven, NY 11719</paragraph>
                  <paragraph>Rev. 05-2025-07</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_412c35f0-f91b-483c-bc84-361bcded1f4e">
               <id root="1fb180f2-9d02-4680-9aaf-eb2b9e57fd56"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Amphetamine (am FET a meen) Sulfate Tablets CII</content>
                  </paragraph>
                  <table width="100%">
                     <col width="17pt"/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about amphetamine sulfate tablets? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Amphetamine sulfate tablets may cause serious side effects, including: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction. </content>Amphetamine sulfate tablets have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of amphetamine sulfate tablets, other amphetamine-containing medicines, and methylphenidate, can lead to overdose and death. The risk of overdosage and death is increased with higher doses of amphetamine sulfate tablets or when it is used in ways that are not approved, such as snorting or injection.
                <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with amphetamine sulfate tablets and will monitor you or your child during treatment.</item>
                                       <item>Amphetamine sulfate tablets may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                       <item>Do not give amphetamine sulfate tablets to anyone else. See <content styleCode="bold">“What are amphetamine sulfate tablets?”</content> for more information.</item>
                                       <item>Keep amphetamine sulfate tablets in a safe place and properly dispose of unused medicine. See <content styleCode="bold">“How should I store amphetamine sulfate tablets?”</content> for more information.</item>
                                       <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Risks for people with serious heart disease. </content>Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you or your child carefully for heart problems before starting amphetamine sulfate tablets. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects. <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with amphetamine sulfate tablets. </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate. </content>Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with amphetamine sulfate tablets.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="underline">Mental (psychiatric) problems, including: </content>
                                    </content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>new or worse behavior and thought problems </item>
                                 <item>new or worse bipolar illness </item>
                                 <item>new psychotic symptoms (such as hearing voices, seeing or believing things that are not real) or new manic symptoms</item>
                              </list>
                              <paragraph>Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with amphetamine sulfate tablets, especially hearing voices, seeing or believing things that are not real, or new manic symptoms. </content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What are amphetamine sulfate tablets? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Amphetamine sulfate tablets are a central nervous system (CNS) stimulant prescription medicine used for the treatment of: </item>
                  </list>
                  <list listType="unordered" styleCode="Circle">
                     <item>
                        <content styleCode="bold">a sleep disorder called narcolepsy. </content>
                     </item>
                     <item>
                        <content styleCode="bold">Attention-Deficit Hyperactivity Disorder (ADHD). </content>
                        <paragraph>Amphetamine sulfate tablets may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD. </paragraph>
                     </item>
                  </list>
                  <list listType="unordered" styleCode="Circle">
                     <item>
                        <content styleCode="bold">exogenous obesity.</content> Amphetamine sulfate tablets may be used as part of a short-term (a few weeks), weight reduction program for obesity in people who have not responded to other treatment.</item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>Amphetamine sulfate tablets are not for use in children with ADHD under 3 years of age. It is not known if amphetamine sulfate tablets are safe and effective in children with exogenous obesity under 12 years of age. </item>
                  </list>
                  <table width="100%" cellspacing="0" cellpadding="0" border="1">
                     <col width="17pt"/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Amphetamine sulfate tablets are a federally controlled substance (CII) because they contain amphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep amphetamine sulfate tablets in a safe place to protect them from theft. Never give your amphetamine sulfate tablets to anyone else, because they may cause death or harm them. Selling or giving away amphetamine sulfate tablets may harm others and is against the law. </content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Do not take amphetamine sulfate tablets if you or your child: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>are allergic to amphetamine products or any of the ingredients in amphetamine sulfate tablets. See the end of this Medication Guide for a complete list of ingredients in amphetamine sulfate tablets </item>
                     <item>are taking or have taken within the past 14 days a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI)</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking amphetamine sulfate tablets, tell your healthcare provider about all of your or your child’s medical conditions, including if you or your child:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>have heart problems, heart disease, heart defects, or high blood pressure </item>
                     <item>have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression</item>
                     <item>have circulation problems in fingers and toes</item>
                     <item>have or have had seizures </item>
                     <item>have or had repeated movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette’s syndrome</item>
                     <item>are pregnant or plan to become pregnant. It is not known if amphetamine sulfate will harm the unborn baby. Tell your healthcare provider if you or your child become pregnant during treatment with amphetamine sulfate tablets.</item>
                     <item>are breastfeeding or plan to breastfeed. Amphetamine sulfate passes into breast milk. You or your child should not breastfeed during treatment with amphetamine sulfate tablets. Talk to your healthcare provider about the best way to feed the baby during treatment with amphetamine sulfate tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines that you or your child takes,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>Amphetamine sulfate tablets and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted during treatment with amphetamine sulfate tablets. </paragraph>
                  <paragraph>Your healthcare provider will decide if amphetamine sulfate tablets can be taken with other medicines. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Especially tell your doctor if you or your child takes: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>selective serotonin reuptake inhibitors (SSRIs)</item>
                     <item>serotonin norepinephrine reuptake inhibitors (SNRIs)</item>
                     <item>medicines used to treat migraine headaches called triptans </item>
                     <item>tricyclic antidepressants</item>
                     <item>lithium </item>
                     <item>fentanyl</item>
                     <item>tramadol</item>
                     <item>tryptophan</item>
                     <item>buspirone</item>
                     <item>St. John’s Wort</item>
                  </list>
                  <paragraph>Know the medicines that you or your child take. </paragraph>
                  <paragraph>Keep a list of your or your child’s medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not start any new medicine during treatment with amphetamine sulfate tablets without talking to your doctor first.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should amphetamine sulfate tablets be taken? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Take amphetamine sulfate tablets exactly as prescribed by your or your child’s healthcare provider. </item>
                     <item>Your healthcare provider may change the dose if needed. </item>
                     <item>The first dose of the day is usually taken when you first wake up. </item>
                     <item>Amphetamine sulfate tablets may cause problems sleeping if taken late in the evening. </item>
                     <item>Amphetamine sulfate tablets should be taken 30 to 60 minutes before meals if it is being used to treat exogenous obesity. </item>
                     <item>If you or your child take too much amphetamine sulfate tablets, call your healthcare provider or Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking amphetamine sulfate tablets?</content>
                  </paragraph>
                  <paragraph>Do not drive, operate machinery, or do other dangerous activities until you know how amphetamine sulfate tablets affect you. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are possible side effects of amphetamine sulfate tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amphetamine sulfate tablets may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>See <content styleCode="bold">"What is the most important information I should know about amphetamine sulfate tablets?"</content>
                     </item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Slowing of growth (height and weight) in children.</content> Children should have their height and weight checked often during treatment with amphetamine sulfate tablets. Your healthcare provider may stop your child’s amphetamine sulfate tablets treatment if they are not growing or gaining weight as expected. </item>
                     <item>
                        <content styleCode="bold">Seizures.</content> Your healthcare provider may stop treatment with amphetamine sulfate tablets if you or your child have a seizure.</item>
                     <item>
                        <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Signs and symptoms may include:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Fingers or toes may feel numb, cool, painful</item>
                           <item>fingers or toes may change color from pale, to blue, to red </item>
                        </list>
                        <paragraph>Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Call your healthcare provider right away if you or your child have any signs or unexplained wounds appearing on fingers or toes during treatment with </content>
                           <content styleCode="bold">amphetamine sulfate tablets.</content>
                        </paragraph>
                     </item>
                     <item>
                        <content styleCode="bold">Serotonin syndrome.</content> This problem may happen when amphetamine sulfate tablets is taken with certain other medicines and may be life-threatening. Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome: </item>
                  </list>
                  <list listType="unordered" styleCode="Circle">
                     <item>agitation, hallucinations, coma </item>
                     <item>confusion </item>
                     <item>fast heartbeat </item>
                     <item>dizziness</item>
                     <item>flushing</item>
                     <item>muscle stiffness or tightness</item>
                     <item>seizures</item>
                     <item>changes in blood pressure</item>
                     <item>sweating or fever </item>
                     <item>high body temperature (hyperthermia)</item>
                     <item>loss of coordination</item>
                     <item>nausea, vomiting, diarrhea </item>
                     <item>
                        <content styleCode="bold">New or worsening tics or worsening Tourette’s syndrome. </content>Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with amphetamine sulfate tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of amphetamine sulfate tablets include: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>headache </item>
                     <item>stomach ache </item>
                     <item>trouble sleeping </item>
                     <item>decreased appetite </item>
                     <item>unpleasant taste </item>
                     <item>nervousness </item>
                     <item>dizziness </item>
                     <item>sexual problems (impotence in males) </item>
                     <item>vomiting </item>
                     <item>itching </item>
                     <item>diarrhea or constipation </item>
                     <item>dry mouth </item>
                     <item>weight loss </item>
                     <item>mood swings </item>
                  </list>
                  <paragraph>These are not all the possible side effects of amphetamine sulfate tablets. </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I store amphetamine sulfate tablets? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store amphetamine sulfate tablets at room temperature between 68°F to 77°F (20°C to 25°C). </item>
                     <item>Store amphetamine sulfate tablets in a safe place, like a locked cabinet.</item>
                     <item>Dispose of remaining, unused, or expired amphetamine sulfate tablets by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix amphetamine sulfate tablets with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away amphetamine sulfate tablets in the household trash. Visit <content styleCode="underline">www.fda.gov/drugdisposal</content> for additional information on disposal of unused medicines.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep amphetamine sulfate tablets and all medicines out of the reach of children. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of amphetamine sulfate tablets. </content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use amphetamine sulfate tablets for a condition for which it was not prescribed. Do not give amphetamine sulfate tablets to other people, even if they have the same symptoms that you or your child have. It may harm them and it is against the law. </paragraph>
                  <paragraph>You can ask your healthcare provider or pharmacist for information about amphetamine sulfate tablets that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in amphetamine sulfate tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient:</content> amphetamine sulfate, USP </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients:</content>  colloidal silicon dioxide, crospovidone, microcrystalline cellulose, stearic acid, and talc. The 10 mg tablets also contain FD&amp;C Blue #1 aluminum lake. </paragraph>
                  <paragraph>For more information about amphetamine sulfate tablets, please contact Amneal Pharmaceuticals at 1-877-835-5472 or visit www.amneal.com. </paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals of New York, LLC<br/>
                     </content>Brookhaven, NY 11719</paragraph>
                  <paragraph>Rev. 05-2025-04</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="LINK_e35c2aef-c704-4a39-9dee-c263e954053d">
               <id root="c1f224dc-1c1a-4487-bfcc-c31e05e2de23"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 69238-1563-1</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amphetamine Sulfate Tablets USP, 5 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals of New York, LLC<br/>
                        <renderMultiMedia referencedObject="MM2"/>
                        <br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 69238-1564-1</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amphetamine Sulfate Tablets USP, 10 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Amneal Pharmaceuticals of New York, LLC</content>
                        <br/>
                        <renderMultiMedia referencedObject="MM3"/>
                        <br/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amphetamine-sulfate-tablets-usp-cii-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amphetamine-sulfate-tablets-usp-cii-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>